San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

In this study of the impact of tucatinib in patients with HER2-positive metastatic breast cancer with stable and active brain metastases, health-related quality of life was maintained, while significant and clinically meaningful improvement in overall survival was observed. Read More ›

To reduce depressive symptoms, behavioral intervention techniques of mindfulness mediation and survivorship education are helpful, according to results from a recent randomized, controlled clinical trial. Read More ›

Retreatment with pertuzumab as either third- or fourth-line chemotherapy was both effective and reasonable in patients with HER2-positive locally advanced/metastatic breast cancer and may be considered a standard treatment practice. Read More ›

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, shares how the San Antonio Breast Cancer Symposium contributes to better care for patients with breast cancer. Read More ›

Interim safety and efficacy analysis of a phase 1b/2 clinical trial of tucatinib, palbociclib, and letrozole in patients with HR-positive and HER2-positive metastatic breast cancer demonstrates antitumor activity and safety profile that warrant future studies. Read More ›

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, discusses the importance of ENHERTU to patients with HER2-positive breast cancer. Read More ›

Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, the addition of tucatinib to trastuzumab and capecitabine showed clinically meaningful improvements in efficacy independent of hormone receptor status. Read More ›

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, suggests ways for patients with cancer to remain safe during the COVID-19 pandemic. Read More ›

In this final overall survival analysis of ExteNET, there were fewer deaths with neratinib despite not reaching statistical significance and greater overall survival with neratinib in subgroups. Read More ›

The healthcare resource utilization of brain metastases is significantly higher among patients with HER2-positive metastatic breast cancer compared with patients without brain metastases, emphasizing the critical need for effective systemic therapies that improve outcomes and decrease the burden of disease. Read More ›

Page 8 of 12

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications